Title

Childhood Immuno-metabolic Markers and Risk of Depression and Psychosis in Adulthood: A Prospective Birth Cohort Study

Article Type

Original Research Paper

Authors

Donnelly NA^{1,2}; Perry BJ^{3,4}; Jones HJ^{1,5,6}; Khandaker, GM^{1,2,3,4,5,6}

Affiliations

¹ Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

² Avon and Wiltshire Mental Health Partnership NHS Trust

³ Department of Psychiatry, University of Cambridge

⁴ Cambridgeshire and Peterborough NHS Foundation Trust

⁵ NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK

⁶ MRC Integrative Epidemiology Unit, University of Bristol

Keywords

ALSPAC; Depression; Psychosis; Leptin; Adipokines; Negative Symptoms

Word Count

Total: 4091 words

Introduction: 613 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

21 Discussion: 1318 words

22 List of Figures and Tables

23 The manuscript includes the following figures:

24 Figure 1: Correlations between Childhood Immuno-metabolic Markers

25 Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and
26 Psychosis Measures

27 Figure 3: Associations of Childhood Immuno-Metabolic Factor Scores with Adult
28 Depression and Psychosis Measures

29 The manuscript includes the following tables:

30 Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and
31 Psychosis Measures in the Whole Sample

32 Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression
33 and Psychosis Measures in the Whole Sample

Abstract

Background

Metabolic and inflammatory disorders commonly co-occur with depression and psychosis, with emerging evidence implicating immuno-metabolic dysfunction in their aetiology. Previous studies have reported metabolic dysfunction and inflammation in adults with depression and psychosis. However, longitudinal studies testing the direction of association, and the effects of different dimensions of early-life immuno-metabolic dysfunction on adult psychopathology, are limited.

Methods

Using data from 3875 birth cohort participants we examined longitudinal associations of three metabolic hormones (leptin, adiponectin, insulin) at age 9 with risks for depression- and psychosis-spectrum outcomes at age 24. In addition, using nine immuno-metabolic biomarkers, we constructed an exploratory bifactor model showing a general immuno-metabolic factor and three specific factors (adiposity, inflammation, and insulin resistance), which were also used as exposures.

Results

Childhood leptin was associated with adult depressive episode (adjusted odds ratio (aOR)=1.28; 95% CI, 1.00-1.64) and negative symptoms (aOR=1.12; 95% CI, 1.05-1.20). The general immuno-metabolic factor was associated with depressive symptoms (aOR=1.05; 95% CI, 1.01-1.08) and psychotic experiences (aOR=1.20; 95% CI, 1.01-1.42). The adiposity factor was associated with negative symptoms (aOR=1.07; 95% CI 1.02-1.12). All associations tended to be stronger in women, though 95% credible intervals overlapped with that for men. In women, the inflammatory factor was associated with depressive episode (aOR=1.23; 95% CI, 1.01-1.47) and atypical depressive symptoms (aOR=1.10; 95% CI, 1.02-1.19).

59 **Conclusions**

60 While general immuno-metabolic dysfunction in childhood may contribute to risks for both
61 psychotic and depressive symptoms in adulthood, childhood adiposity and inflammation are
62 linked to affective (depressive, atypical, and negative) symptoms.

1. Introduction

Immuno-metabolic alterations are present in depressive and psychotic disorders, and are associated with excess mortality (Hoang et al., 2013; Milaneschi et al., 2020, 2019; Vancampfort et al., 2015). The prevalence of cardiometabolic disease (Penninx et al., 2001; van Melle et al., 2004), autoimmune inflammatory conditions (Benros et al., 2011; Eaton et al., 2006), and levels of circulating inflammatory markers (Khandaker et al., 2014; Osimo et al., 2019), are higher in people with depression and psychosis compared with controls. However, the direction of these relationships remains unclear. For example, while psychotropic medications can increase predisposition to cardiometabolic disorders (Vancampfort et al., 2015), there is evidence that predisposition towards cardiometabolic dysfunction predates treatment with psychotropic medications (Benseñor et al., 2012; Perry et al., 2016, 2021b; Pillinger et al., 2017). Therefore, longitudinal studies are required to address the issue of direction of association.

Emerging evidence from longitudinal studies suggests that inflammation may predate the onset of depression and psychosis. Using longitudinal data from the Avon Longitudinal Study of Parents and Children (ALSPAC) and Northern Finland Birth Cohort (NFBC) 1986 birth cohorts (Khandaker et al., 2014; Metcalf et al., 2017; Perry et al., 2021b), we have reported associations between higher circulating levels of interleukin 6 (IL-6) and C-reactive protein (CRP) in childhood and adolescence with risk of depression and psychosis subsequently in adulthood. Similar longitudinal associations have also been reported from the UK Whitehall (Gimeno et al., 2009), Dutch Generation R (Zalli et al., 2016) and the Netherlands Study of Depression and Anxiety (NESDA) (Lamers et al., 2020) cohorts. Using longitudinal repeated measures data from the ALSPAC cohort, we have reported higher risk of psychosis in adulthood associated with persistently high insulin levels across childhood, adolescence and early-adulthood, which may vary by sex (Perry et al., 2021b). These findings point to a role of immuno-metabolic alterations in childhood, a critical period for the development of the nervous, immune, and endocrine systems, in the aetiology of psychiatric disorders.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Despite previous studies reporting obesity, altered glucose-insulin homeostasis, lipids, and other metabolic dysfunction in people with depression, psychosis and young people with psychotic experiences (Milaneschi et al., 2019; Perry et al., 2019; Vancampfort et al., 2015), longitudinal studies of childhood metabolic markers and subsequent depression and psychosis are relatively scarce. Particularly lacking are studies of metabolic hormones such as insulin, adiponectin and leptin, which are key neuroendocrine regulators of energy homeostasis. Immuno-metabolic biomarkers are interlinked and have pleiotropic functions. For instance, obesity is associated with systemic low-grade inflammation (Timpson et al., 2011; Yudkin et al., 1999), while insulin and leptin are influenced by inflammation and obesity (Considine et al., 1996; Jerry and Lesley, 2006; van Dielen et al., 2001). Commonly known as a satiety hormone, leptin is structurally similar to IL-6 and may have inflammatory functions (Abella et al., 2017). Additionally, previous studies have typically considered only a few immune or metabolic markers in isolation and ignored the underlying structure of covariance between biomarkers.

To address the issue of direction of association, we have carried out a longitudinal study testing the associations of three key metabolic hormones (insulin, leptin and adiponectin), measured in childhood at age 9 years, with several outcomes across the spectrum of depression (depressive episode, total symptom score, and atypical symptom score) and psychosis (psychotic disorder, at-risk mental state, psychotic experiences, negative symptoms) at age 24 years, in a whole analysis sample and in men and women separately, using data from the ALSPAC birth cohort. Furthermore, combining these hormones with related immuno-metabolic markers (BMI, LDL, HDL, triglycerides, IL-6, and CRP), also measured at age 9, we identified factors representing general and specific dimensions of early-life immuno-metabolic dysfunction, and tested their associations with psychiatric outcomes at age 24.

2. Materials and Methods

2.1 Cohort Profile

We used data from the ALSPAC birth cohort (Boyd et al., 2013; Fraser et al., 2013; Northstone et al., 2019), which recruited 14,541 pregnant women in the Avon area of the United Kingdom between 1990 and 1992; of these initial pregnancies 13,988 children were alive at 1 year of age. Further phases of recruitment occurred when the oldest children in the cohort were approximately 7 years of age, resulting in an additional 913 children being enrolled; giving a total cohort size of 15,454 pregnancies, resulting in 15,589 deliveries, of which 14,901 were alive at 1 year of age. The study is considered to be representative of the UK population (Golding et al., 2001).

Study data are collected and managed using the REDCap (Research Electronic Data Capture) tools hosted at the University of Bristol (Harris et al., 2019, 2009). Children and parents have been subsequently followed up with clinic and questionnaire assessments for a range of health outcomes. The ALSPAC study website contains details of all available data through a fully searchable data dictionary <http://www.bristol.ac.uk/alspac/researchers/our-data/>.

Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (<http://www.bristol.ac.uk/alspac/researchers/research-ethics/>). Consent for biological samples was collected in accordance with the UK Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

This study is reported in line with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

2.2 Measurement of childhood immuno-metabolic biomarkers at age 9

2.2.1 Metabolic Hormones

Leptin, adiponectin and random insulin were measured at the cohort age 9 clinic visit (**Supplementary Table 1**). As previously described (Falaschetti et al., 2010), non-fasting blood samples were collected during clinic visits, using standard aseptic procedure and immediately spun and frozen for long-term storage at -80°C. Blood biomarkers were assayed in 2008 after a median of 7.5 years in storage with no previous freeze–thaw cycles during storage. We did not include fasting insulin in this study due to the lower sample size available for that measure (Ong et al., 2004). Leptin (ng/ml) was measured by an in-house enzyme-linked immunosorbent assay (ELISA) validated against commercial methods. Adiponectin (ng/ml) and random insulin (mU/l) was measured using an ultrasensitive automated microparticle enzyme immunoassay (Mercodia), which does not cross-react with proinsulin. All assay coefficients of variation were <6%.

2.2.2 Other Metabolic Biomarkers

We included plasma lipids (LDL, HDL and triglycerides (mmol/l)), also measured at the cohort age 9 clinic visit (**Supplementary Table 1**). All were measured by a modification of the standard Lipid Research Clinics Protocol using enzymatic reagents for lipid determination.

2.2.3 Inflammatory Biomarkers

We included IL-6 and CRP, which were also measured at the cohort age 9 clinic visit (**Supplementary Table 1**). IL-6 (pg/ml) was measured by ELISA (R&D systems, Abingdon, UK), and CRP (mg/l) was measured by automated particle-enhanced immunoturbidimetric assay (Roche UK, Welwyn Garden City, UK).

2.3 Assessment of Psychiatric Outcomes at age 24

2.3.1 Psychosis-Spectrum Outcomes

Psychotic positive symptoms were measured at age 24 with the psychosis-like symptoms (PLIKS) interview (Sullivan et al., 2020; Zammit et al., 2013). Interviews were undertaken using a semi-structured format by trained psychologists. Psychotic experiences (PEs) were defined as symptoms in 3 domains (hallucinations, delusions, and thought interference) occurring in the 6 months prior to the interview. After cross-questioning, PEs were rated as absent, suspected, or definite. We included definite PEs as our outcome of interest.

Psychotic disorder was defined as definite PLIKS, not attributable to sleep or fever, which occurred at least once a month in the past 6 months, which either caused the respondent to seek professional help, was very upsetting/distressing, and/or had a negative impact on their social/occupational life.

Cases of At Risk Mental State (ARMS) were defined by mapping the Comprehensive Assessment of the At Risk Mental State (CAARMS) criteria onto the PLIKS variables (Perry et al., 2021b). ARMs were defined as participants meeting CAARMS criteria for attenuated psychosis (symptoms not reaching the psychosis threshold owing to levels of intensity or frequency), brief limited intermittent psychosis (frank psychotic symptoms that resolved spontaneously within 1 week), or the CAARMS psychosis group.

Negative symptoms at age 24 were measured using ten questions from a self-administered, computerised version of the Community Assessment of Psychic Experiences (CAPE) questionnaire (Jones et al., 2016; Konings et al., 2006; Stefanis et al., 2002). We generated a single outcome variable by dichotomising responses to each question (each item was rated by participants on a 1-4 scale, we grouped responses 1 and 2 as “symptom present”, scoring 1 and responses 3 and 4 as “symptom absent”, scoring 0) and summing the resultant scores, giving each participant a negative symptom score from 0 - 10.

2.3.2 Depression Outcomes

Depressive symptoms at age 24 were measured using a self-administered, computerised version of the Clinical Interview Schedule, Revised (CIS-R) (Lewis et al., 1992). We took three outcomes from the CIS-R data: (1) a dichotomous depressive episode variable, based on a mapping of the CIS-R responses onto ICD-10 depression diagnostic criteria; (2) a symptom score which was constructed as a sum of scores of the mood, thoughts, fatigue, concentration, and sleep components for the CIS-R. This score ranged between 0 and 20. We also derived (3): an atypical depression symptoms score composed of the sum of participants scores on 4 items from the CIS-R: increased appetite, increased weight, hypersomnia and low energy. Note that the CIS-R does not contain a measure of “leaden paralysis” as has been included in other measures of atypical depression (Lamers et al., 2020), as this measure is not part of many common depression screening instruments (Fried, 2017).

2.3.3 Confounders

We included maternal social class (determined using occupational status) and maternal highest educational level as potential confounders. IL-6 and BMI at age 9 (weight in kg divided by height in meters squared) were also included for analyses where they were not part of the predictors.

2.4 Statistical Analysis

2.4.1 Data Transformation

We log₁₀-transformed all metabolic measures to give approximately normally distributed data, except for adiponectin, which was already approximately normally distributed. All continuous exposure and covariate variables were centred and standardised (mean value subtracted and then divided by the standard deviation). Therefore, odds ratios (ORs) represent change in outcome per SD change in exposure.

2.4.2 Exploratory Factor Analysis

Using adiponectin, insulin, leptin, IL-6, CRP, HDL, LDL, triglycerides, and BMI, we explored the underlying factor structure of the immuno-metabolic phenotype at age 9. Before analysis, we inverted HDL to match the cardiometabolic risk-increasing direction of other markers.

Factor analysis was done using the exploratory factor analysis (EFA) function in the *EFAtools* R package. The number of factors was selected after inspecting the results of a principal components analysis (**Supplementary Methods, Supplementary Figure 2**). We fit a one factor, three factor, and a bifactor model with 3 subfactors, and compared model fit (**Supplementary Table 2**). Compared to a one- or 3-factor model, the bifactor model was a better fit to our data. We then extracted factor scores for each factor for each subject (**see Supplementary Figure 2 and Supplementary Table 3 for factor loadings**).

2.4.3 Modelling Approach

We analysed data using R version 4.1.0 (R Development Core Team, 2017), fitting Bayesian regression models using the *brms* (Bürkner, 2017) and *rstanarm* packages (Carpenter et al., 2017). As the number of participants providing data for different outcomes varied, we fit each model to the largest possible dataset of complete cases for all covariates, exposures and outcomes (**see Supplementary Tables 4-6 for full details**).

We fit unadjusted models with a psychiatric outcome predicted by our exposure variables of interest (leptin, adiponectin and insulin). Next, we fit adjusted models with BMI at age 9, log₁₀ IL-6, sex at birth and maternal socioeconomic class included as covariates. We also fit adjusted sex-stratified models to all female and male participants separately. For models using factor scores as exposures, we included all factor scores as exposures plus sex at birth and maternal socio-economic class as covariates.

We used regularising priors for all models (McElreath, 2018), calculating model estimate and the 95% credible interval, using the median and the highest density interval method. We present as summary statistics the probability of direction, which can be considered

analogous to the frequentist p-value (Makowski et al., 2019a, 2019b), and the Region of Practical Equivalence (ROPE), the proportion of the posterior falling within a set region around the null, here defined as an odds ratio in the range 0.9 – 1.1 (Kruschke and Liddell, 2018). **See supplementary methods for further details.**

2.4.4 Missing data

We analysed missingness in the dataset with two models: a model for missingness of clinic data at age 9, with predictors of maternal education, maternal social class and ethnicity and sex of the child; and a model for missingness for age 24 psychiatric data in the set of participants who had blood tests at age 9, with predictors of maternal education, maternal social class, ethnicity and sex of the child, and age 9 adiponectin, random insulin and leptin, IL-6 and BMI.

2.4.5 Data Availability

In line with the ALSPAC data access policy, all raw data used for the work presented can be accessed by other investigators by making a request to the ALSPAC study executive (see <http://www.bristol.ac.uk/alspac/researchers/access/>).

3. Results

3.1 Childhood immuno-metabolic biomarker distributions, correlates, and factor score calculation

Data on three metabolic hormones (insulin, leptin, adiponectin) and six related immuno-metabolic biomarkers (BMI, HDL, LDL, triglycerides, IL-6, and CRP) were available from total 3,875 participants at age 9 (**Supplementary Table 1**).

Higher leptin was associated with higher BMI (beta = 0.71; 95% credible interval [CI] 0.69-0.73), female sex (beta for girls compared to boys = 0.48; 95% CI 0.44 - 0.51) and higher IL-6 (beta = 0.04; 95% CI 0.02-0.05). Higher adiponectin was associated with lower BMI (beta = -0.14; 95% CI -0.16 - -0.11), female sex (beta = 0.12; 95% CI 0.07-0.18) and higher IL-6 (beta = 0.04; 95% CI 0.01-0.06). Higher insulin was associated with higher BMI (beta = 0.22; 95% CI 0.19-0.25, **see Supplementary Figure 1 and Supplementary Table 7**).

Immuno-metabolic biomarkers were correlated (correlations ranged from -0.18 for adiponectin-HDL to 0.75 for leptin-BMI, **Figure 1**). Using data for nine biomarkers we calculated a bifactor model identifying a general immuno-metabolic factor (G, loading on all biomarkers), and three sub-factors representing: (1) adiposity (loading on higher BMI, leptin and LDL); (2) inflammation (loading on higher IL-6 and CRP); and (3) insulin resistance (loading on higher triglycerides, insulin and lower HDL, **Supplementary Table 3**). There was no relationship between sex or maternal class and G; all sub-factors had higher mean values in females (**Supplementary Table 8**).

Figure 1: Correlation between immuno-metabolic biomarkers at age 9 in the ALSPAC birth cohort.

Matrix of correlations between all 9 immuno-metabolic markers measured at age 9. Colour represents correlation; negative correlations are represented in blue, positive correlations in red. Numerical values are correlation coefficients.

3.2 Associations of childhood metabolic hormones with depression and psychosis risk in adulthood

3.2.1 Whole Sample Analysis

After adjusting for potential confounders, leptin at age 9 was associated with depressive episode (adjusted odds ratio [aOR] =1.28; 95% CI, 1.00-1.64) and negative symptoms at age 24 (aOR=1.12; 95% CI 1.05-1.20). Adiponectin was also associated with negative symptoms (aOR=1.05; 95% CI 1.00-1.09 **Figure 2, Table 1**). Insulin was not associated with any psychiatric outcome in our total sample.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and Psychosis Measures in the Whole Sample

Plots of estimated odds ratios for the effect of our exposures (adiponectin, insulin and leptin) on psychiatric outcomes at age 24. Data are presented unadjusted and adjusted (for sex in the all-participant model, IL-6 at age 9, BMI at age 9 and maternal social class) and grouped by model: all participants, only females or only males. Thin bars represent the 95% credible interval, thicker bars the 66% credible interval, and dots the median of the posterior distribution for that parameter.

300 *Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and Psychosis Measures in the Whole Sample*

Outcome	Exposure	Unadjusted Analysis			Adjusted Analysis		
		Estimated OR (95% CI)	pd	ROPE (%)	Estimated OR (95% CI)	pd	ROPE (%)
Depressive Episode	Leptin	1.24 (1.06, 1.46)	0.009	7.73	1.28 (1.00, 1.64)	0.055	12.64
	Adiponectin	1.03 (0.88, 1.20)	0.692	74.39	1.00 (0.85, 1.17)	0.996	76.58
	Insulin	1.02 (0.88, 1.20)	0.796	76.26	1.05 (0.88, 1.23)	0.607	69.80
Depressive Symptoms Score	Leptin	1.08 (1.04, 1.11)	< 0.001	93.48	1.03 (0.97, 1.08)	0.374	99.64
	Adiponectin	0.99 (0.96, 1.02)	0.519	100.00	0.99 (0.95, 1.02)	0.437	100.00
	Insulin	1.01 (0.98, 1.04)	0.549	100.00	1.01 (0.98, 1.05)	0.456	100.00
Atypical Depressive Symptoms Score	Leptin	1.11 (1.04, 1.18)	0.002	45.73	1.00 (0.90, 1.10)	0.987	95.25
	Adiponectin	1.00 (0.94, 1.07)	0.937	99.88	1.00 (0.94, 1.06)	0.985	99.86
	Insulin	0.98 (0.93, 1.05)	0.611	99.70	0.98 (0.93, 1.04)	0.572	99.71
Negative Symptoms Score	Leptin	1.04 (0.99, 1.08)	0.103	99.83	1.12 (1.05, 1.20)	0.001	33.27
	Adiponectin	1.05 (1.01, 1.10)	0.015	98.78	1.05 (1.00, 1.09)	0.038	99.25
	Insulin	1.02 (0.98, 1.06)	0.400	100.00	1.02 (0.98, 1.07)	0.296	99.94
Psychotic Experiences	Leptin	1.14 (0.96, 1.36)	0.161	35.93	0.96 (0.73, 1.27)	0.760	50.54
	Adiponectin	0.97 (0.80, 1.16)	0.779	70.13	1.01 (0.84, 1.21)	0.924	71.41
	Insulin	1.16 (0.97, 1.39)	0.100	30.24	1.13 (0.95, 1.37)	0.182	39.36
Psychotic Disorder	Leptin	1.11 (0.73, 1.60)	0.604	34.23	1.23 (0.75, 2.06)	0.433	22.66

	Adiponectin	1.05 (0.71, 1.53)	0.817	38.34	1.01 (0.66, 1.48)	0.957	37.18
	Insulin	1.09 (0.73, 1.59)	0.674	35.45	1.11 (0.74, 1.62)	0.589	33.36
Psychosis ARMS	Leptin	0.95 (0.61, 1.40)	0.793	36.58	1.21 (0.72, 2.00)	0.449	22.96
	Adiponectin	0.98 (0.65, 1.45)	0.938	37.08	0.94 (0.63, 1.39)	0.780	36.27
	Insulin	0.87 (0.59, 1.26)	0.494	31.34	0.91 (0.62, 1.31)	0.629	34.92

301

3.2.2 Sex-Stratified Analysis

The associations of leptin with depressive episode (aOR=1.42; 95% CI 1.04-1.91), depressive symptoms (aOR=1.09; 95% CI 1.01-1.18) and negative symptoms (aOR=1.18; 95% CI 1.07-1.29) were stronger in women, as was the associations of adiponectin (aOR=1.07; 95% CI 1.01-1.13) and of insulin (aOR =1.08; 95% CI 1.01-1.14) with negative symptoms, although credible intervals overlapped with those for men (**Supplementary Tables 9&10**).

3.3 Associations of childhood immuno-metabolic factor scores with depression and psychosis risk in adulthood

3.3.1 Whole Sample Analysis

The general immuno-metabolic factor, G, was associated with depression symptom score (OR=1.05; 95% CI 1.01-1.08) and psychotic experiences at age 24 (aOR=1.20; 95% CI 1.01-1.42, **Figure 3, Table 2**). The adiposity factor was associated with negative symptoms (aOR=1.07; 95% CI 1.02-1.12).

3.3.2 Sex-Stratified Analysis

There was stronger evidence of association between G and psychopathology in women than men. In women, G was associated with depression symptom score (aOR=1.05; 95% CI 1.01-1.09), atypical depression (aOR=1.07; 95% CI 1.00-1.15), and psychotic experiences (aOR=1.25; 95% CI 1.01-1.52, **Supplementary Tables 11&12**) although credible intervals overlapped with those for men.

The inflammatory factor was associated with depressive episodes (aOR=1.23; 95% CI 1.01-1.47) and atypical depressive symptoms in women (aOR=1.10; 95% CI 1.02-1.19). The adiposity factor was associated with negative symptoms in women (aOR=1.09; 95% CI 1.03-1.16). The insulin resistance factor was not associated with any psychiatric outcomes at age 24. However, point estimates for the association between the insulin resistance factor and psychosis-related outcomes (PEs, ARMS, psychotic disorder) were considerably larger in men compared with women, although credible intervals were relatively wide (**Figure 3**).

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Figure 3: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and Psychosis Measures in the Whole Sample

Plots of estimated odds ratios for the effect of factor scores derived from a bifactor EFA model (general factor (G) and three subfactors:(1) adiposity (ADI), (2) inflammation (INF) and (3) insulin resistance (IR) on psychiatric outcomes at age 24. Data are adjusted (for maternal social class and sex in the all-participant model) and grouped by model: either all participants, only females or only males. Thin bars represent the 95% credible interval, thicker bars the 66% credible interval, and dots the median of the posterior distribution for that parameter.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

338 *Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and*
339 *Psychosis Measures in the Whole Sample*

Outcome	Exposure (Immuno-metabolic Factors)	Estimated OR (95% CI)	pd	ROPE (%)
Depressive Episode	General factor	1.02 (0.87, 1.18)	0.843	79.33
	Adiposity factor	1.14 (0.97, 1.35)	0.121	34.71
	Inflammation factor	1.13 (0.97, 1.33)	0.141	40.11
	Insulin resistance factor	1.04 (0.88, 1.22)	0.670	73.37
Depressive Symptoms Score	General factor	1.05 (1.01, 1.08)	0.008	99.97
	Adiposity factor	1.03 (0.99, 1.07)	0.107	99.98
	Inflammation factor	0.99 (0.96, 1.03)	0.626	100.00
	Insulin resistance factor	0.98 (0.95, 1.02)	0.328	100.00
Atypical Depressive Symptom Score	General factor	1.06 (1.00, 1.12)	0.063	93.41
	Adiposity factor	1.03 (0.97, 1.10)	0.339	98.12
	Inflammation factor	1.06 (1.00, 1.13)	0.069	91.38
	Insulin resistance factor	0.99 (0.93, 1.05)	0.796	99.83
Negative Symptoms Score	General factor	0.97 (0.93, 1.01)	0.130	99.92
	Adiposity factor	1.07 (1.02, 1.12)	0.005	92.45
	Inflammation factor	1.03 (0.99, 1.07)	0.191	99.98
	Insulin resistance factor	1.00 (0.95, 1.04)	0.861	100.00
Psychotic Experiences	General factor	1.20 (1.01, 1.42)	0.029	15.84
	Adiposity factor	1.12 (0.93, 1.36)	0.226	41.93
	Inflammation factor	1.02 (0.85, 1.22)	0.850	69.88
	Insulin resistance factor	0.97 (0.81, 1.16)	0.754	70.36
Psychotic Disorder	General factor	0.90 (0.62, 1.32)	0.570	34.57
	Adiposity factor	1.09 (0.72, 1.59)	0.673	34.12
	Inflammation factor	1.27 (0.86, 1.82)	0.234	19.64

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

	Insulin resistance factor	1.10 (0.75, 1.65)	0.621	33.89
Psychosis ARMS	General factor	0.76 (0.50, 1.13)	0.171	16.25
	Adiposity factor	0.98 (0.63, 1.47)	0.942	35.86
	Inflammation factor	0.96 (0.64, 1.44)	0.854	36.54
	Insulin resistance factor	1.17 (0.79, 1.73)	0.427	28.33

340

341 3.4 Missing Data

342 Out of total 15,645 participants enrolled in ALSPAC at inception, 3,875 contributed clinic and
 343 covariate data up to age 9, and up to 3,966 participants contributed psychiatric data at age 24
 344 (**Supplementary Table 13**). A maximum of 1,611 participants contributed both exposure and
 345 outcome data (~10% of the total cohort, ~40% of all participants with outcome data). Therefore,
 346 there was substantial missingness in our dataset.

347 In a sample of participants who contributed all demographic, age 9 immuno-metabolic exposures
 348 and covariate data (n = 3,863), male sex (aOR=2.32; 95% CI 2.02-2.68), lower maternal education
 349 (aOR=0.39; 95% CI 0.29-0.50), lower maternal social class (aOR=0.62; 95% CI 0.40-0.95), and
 350 higher adiponectin levels at age 9 (aOR=1.08; 95% CI 1.01-1.16) were associated with missing
 351 psychiatric outcome data at age 24 (**Supplementary Table 14**).

4. Discussion

4.1 Main Findings

Using data from a prospective birth cohort, we report that childhood leptin and adiponectin are associated with largely affective symptoms (depression and psychosis negative symptoms) in adulthood. Evidence for these associations remained after controlling for covariates including BMI and inflammation and was stronger in women. Exploratory Factor Analysis of metabolic and inflammatory biomarkers revealed an underlying structure of covariance, where a general immuno-metabolic factor was associated with both depressive symptoms and psychotic experiences. We also identified three specific factors. Leptin and BMI loaded onto the adiposity factor, which was associated with negative symptoms. The inflammatory factor was associated with depressive episode and atypical depressive symptoms in women. We found no associations between the insulin resistance factor and psychiatric outcomes, although the point estimates for psychosis-related outcomes were considerably larger in men than women.

4.2 Comparison with Previous Studies

The association between leptin and negative symptoms is in keeping with a meta-analysis of patients with schizophrenia (Stubbs et al., 2016), although this was not observed in smaller studies of first episode of psychosis (FEP) patients (Chouinard et al., 2019; Lis et al., 2020). However, in FEP cases Lis et al., (2020) observed a correlation between leptin and cognitive dysfunction, a domain of psychopathology somewhat linked to negative symptoms. Recently, a Mendelian randomisation (MR) study did not find an association between leptin and schizophrenia (Perry et al., 2021a), bringing into question whether leptin plays a causal role in the illness. It is worth noting that this MR analysis relied on GWAS of schizophrenia, and not that of negative symptoms specifically. Therefore, replication of our findings in other longitudinal cohorts, as well as evidence triangulation using complementary methods like MR based on GWAS of negative symptoms are required to fully understand the relationship between leptin and negative symptoms.

Lack of association between childhood random insulin levels, or the insulin resistance factor, and positive psychotic symptoms at age 24 is consistent with a previous study from the ALSPAC cohort

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

testing association between fasting insulin and psychosis-spectrum outcomes at age 18 (Perry et al., 2019). However, using longitudinal repeat measure data, Perry et al., (2021b) recently reported that persistently raised fasting insulin levels through childhood and adolescence is associated with psychosis risk at age 24. Together, these findings suggest that persistently high leptin during development is likely relevant for adult psychosis, rather than one-off measures which do not consider variation in leptin levels over time. Nevertheless, similar to Perry et al., (2021b), we observed stronger association between the insulin resistance factor and psychosis-related outcomes in men compared with women, suggesting that early-life insulin resistance may contribute to psychosis risk in men particularly.

4.3 Potential mechanism of associations of immuno-metabolic markers and depressive and psychotic symptoms

We observed that adiposity and inflammation were largely associated with negative and atypical depressive symptoms. There is a rich literature suggesting a role of low-grade systemic inflammation in depression (Khandaker et al., 2017; Milaneschi et al., 2021, 2020). Our findings are consistent with a previous genetic study showing that cases of atypical depression (defined by increased appetite and/or weight) have higher genetic predisposition for obesity and inflammation, particularly genetic risk variants for BMI, leptin, and CRP (Milaneschi et al., 2017). Similarly, recent MR studies from the UK Biobank and Dutch NESDA cohorts have reported associations of higher BMI and IL-6 with specific depressive symptoms such as fatigue and appetite change (Kappelmann et al., 2021; Milaneschi et al., 2021). The mechanism of the association between inflammation and depression, particularly atypical depressive symptoms (Lamers et al., 2020), has been hypothesised to involve the activation of sickness-related behaviours by inflammatory cytokines, which directly affect neuroendocrine systems involved in regulating mood and homeostatic functions such as sleep and appetite (Milaneschi et al., 2020). Further work is needed to understand how leptin, and adiposity in general, contribute to negative symptoms.

Negative symptoms are common in schizophrenia, with prevalence exceeding 50% (Bobes et al., 2010), and are a major contributor to morbidity (Fervaha et al., 2014; Iasevoli et al., 2018).

Furthermore, there is only a limited evidence base for effective treatments for these symptoms

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

(Galderisi et al., 2021). Previous work suggests two latent factors underlying negative symptoms, namely reduced expression and amotivation (Bucci and Galderisi, 2017). Studies in schizophrenia suggest an association between amotivational negative symptoms and altered reward processing, which involves brain regions associated with the dopamine system including the ventral striatum and medial prefrontal cortex (Strauss et al., 2016; Vanes et al., 2018; Wang et al., 2015; Wolf et al., 2014). Leptin has been demonstrated to both indirectly and directly affect the activity of midbrain dopamine neurons in animal models (Hommel et al., 2006; Leininger et al., 2009), as has adiponectin (Sun et al., 2019). Furthermore, a relationship between inflammation, brain reward systems and negative symptoms has been proposed (Goldsmith and Rapaport, 2020), which leptin could also modulate, given evidence of its interactions with immune system (Abella et al., 2017; Pulito-Cueto et al., 2020). Therefore, adipokines could have a direct influence on immune and neural networks involved in the pathogenesis of negative symptoms.

4.4 Strengths and Limitations

We used prospective data with exposures measured approximately 15 years prior to that of outcomes. We used a Bayesian approach to our statistical analysis, which is relatively novel and allowed the incorporation of prior information, and the generation of point estimates and credible intervals which have a more intuitive and robust interpretation than frequentist confidence intervals and p-values (Wagenmakers et al., 2018).

Limitations include missing data and pattern of missingness. Participants were not missing completely at random. Analysis of missingness in exposure data revealed that social class, and education influenced participation in the study. The complete case data came from a group from higher social class and higher educated families. One of the exposures, adiponectin, was associated with missingness, which might have introduced bias. Furthermore, >97% of the ALSPAC cohort is of white ethnicity, and so representativeness is an issue, and further studies in more diverse populations are required.

We used an exploratory factor analysis approach to derive immuno-metabolic factors. In future, confirmation of these findings in an independent dataset using confirmatory factor analysis is

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

required. Bifactor models have a tendency to overfitting (Bonifay and Cai, 2017) and we were limited to nine immuno-metabolic biomarkers available from the age 9 ALSPAC cohort clinic assessment. In future, inclusion of a wider range of biomarkers may help to improve latent factor estimation. Nevertheless, without pre-specifying the biomarkers that might contribute to each latent factor, we identified three specific factors (adiposity, inflammation, and insulin resistance) composed of individual biomarkers with established, intuitive links with each factor, giving our findings face validity.

Methods for calculating factor scores are imprecise, and scores are inherently indeterminate (Grice, 2001). Therefore, the use of extracted factor scores as exposures in separate models may have introduced error. However, the approach of combining factor scores with other datasets for further analysis, including by Bayesian approaches, has been previously applied (Dam et al., 2017; Gagne et al., 2020), and can contribute exploratory information to inform future studies. A future approach that combines (potentially longitudinally measured) biomarkers with latent factors and psychiatric outcomes in a single (Bayesian) structural equation model might inform a deeper understanding of the relationship between individual biomarkers, useful intermediate concepts (latent factors), and individual symptoms or psychopathological constructs.

4.5 Conclusions

Using a prospective cohort study, we report that childhood levels of the metabolic hormones leptin and adiponectin are associated with depressive and negative symptoms in early adulthood. These associations are stronger in women than men. Somewhat distinct associations were seen for immuno-metabolic factor scores, which were derived from nine immuno-metabolic measures. While a general immuno-metabolic factor was associated with both depressive and psychotic symptoms, inflammation and adiposity were particularly associated with affective (depressive, atypical depressive, and negative) symptoms. Together, these findings are consistent with the idea that childhood immuno-metabolic alterations may contribute to risk of depressive and psychotic disorders in adulthood.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Acknowledgements

The authors would like to thank Nils Kappelman for valuable discussions about statistical analysis and atypical depression. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Funding Sources

The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grant funding is available on the ALSPAC website (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>).

The outcome data from age 24 was specifically funded by MRC grants MR/L022206/1 and MR/M006727/1.

NAD acknowledges funding support from a National Institute for Health Research Academic Clinical Fellowship in Mental Health. BIP acknowledges funding support from the National Institute for Health Research (NIHR) (Doctoral Research Fellowship Grant No. DRF-2018-11-ST2-018). HJJ acknowledges support from the NIHR Bristol Biomedical Research Centre. GMK acknowledges funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z), the Medical Research Council (Grant No. MC_PC_17213, Grant No. MR/S037675/1, and Grant No. MR/W014416/1), The MQ: Transforming Mental Health (Grant No. MQDS17/40), and the BMA Foundation (J. Moulton Grant 2019).

Competing Interests

The authors declare they have no competing interests

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

CRediT author statement

Nicholas Donnelly: Conceptualisation; Software; Data Curation; Formal Analysis; Visualization; Writing – Original Draft

Benjamin Perry: Data Curation; Writing – Review & Editing

Hannah Jones: Writing – Reviewing & Editing

Golam Khandaker: Conceptualization; Supervision; Writing – Reviewing & Editing; Funding acquisition

References

- Abella, V., Scotece, M., Conde, J., Pino, J., Gonzalez-Gay, M.A., Gómez-Reino, J.J., Mera, A., Lago, F., Gómez, R., Gualillo, O., 2017. Leptin in the interplay of inflammation, metabolism and immune system disorders. *Nat. Rev. Rheumatol.* 13, 100–109.
<https://doi.org/10.1038/nrrheum.2016.209>
- Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., 2011. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. *Am. J. Psychiatry* 168, 1303–1310.
<https://doi.org/10.1176/appi.ajp.2011.11030516>
- Benseñor, I.M., Brunoni, A.R., Pílan, L.A., Goulart, A.C., Busatto, G.F., Lotufo, P.A., Scazufca, M., Menezes, P.R., 2012. Cardiovascular risk factors in patients with first-episode psychosis in São Paulo, Brazil. *Gen. Hosp. Psychiatry* 34, 268–275.
<https://doi.org/10.1016/j.genhosppsych.2011.12.010>
- Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., CLAMORS Study Collaborative Group, 2010. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. *J. Clin. Psychiatry* 71, 280–286. <https://doi.org/10.4088/JCP.08m04250yel>
- Bonifay, W., Cai, L., 2017. On the Complexity of Item Response Theory Models. *Multivar. Behav. Res.* 52, 465–484. <https://doi.org/10.1080/00273171.2017.1309262>
- Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, A., Ring, S., Davey Smith, G., 2013. Cohort Profile: The ‘Children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. *Int. J. Epidemiol.* 42, 111–127.
<https://doi.org/10.1093/ije/dys064>
- Bucci, P., Galderisi, S., 2017. Categorizing and assessing negative symptoms. *Curr. Opin. Psychiatry* 30, 201–208. <https://doi.org/10.1097/YCO.0000000000000322>
- Bürkner, P.-C., 2017. brms: An R Package for Bayesian Multilevel Models Using Stan. *J. Stat. Softw.* 80, 1–28. <https://doi.org/10.18637/jss.v080.i01>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 518 Carpenter, B., Gelman, A., Hoffman, M.D., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo,
519 J., Li, P., Riddell, A., 2017. Stan: A Probabilistic Programming Language. J. Stat. Softw. 76, 1–
520 32. <https://doi.org/10.18637/jss.v076.i01>
- 521 Chouinard, V.-A., Henderson, D.C., Man, C.D., Valeri, L., Gray, B.E., Ryan, K.P., Cypess, A.M.,
522 Cobelli, C., Cohen, B.M., Öngür, D., 2019. Impaired insulin signaling in unaffected siblings and
523 patients with first episode psychosis. Mol. Psychiatry 24, 1513–1522.
524 <https://doi.org/10.1038/s41380-018-0045-1>
- 525 Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R.,
526 Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L., Caro, J.F., 1996. Serum
527 Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. N. Engl. J. Med.
528 334, 292–295. <https://doi.org/10.1056/NEJM199602013340503>
- 529 Dam, N.T.V., O'Connor, D., Marcelle, E.T., Ho, E.J., Craddock, R.C., Tobe, R.H., Gabbay, V.,
530 Hudziak, J.J., Castellanos, F.X., Leventhal, B.L., Milham, M.P., 2017. Data-Driven Phenotypic
531 Categorization for Neurobiological Analyses: Beyond DSM-5 Labels. Biol. Psychiatry 81, 484–
532 494. <https://doi.org/10.1016/j.biopsych.2016.06.027>
- 533 Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.-Y., Agerbo, E., Mortensen, P.B., 2006.
534 Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.
535 Am. J. Psychiatry 163, 521–528. <https://doi.org/10.1176/appi.ajp.163.3.521>
- 536 Falaschetti, E., Hingorani, A.D., Jones, A., Charakida, M., Finer, N., Whincup, P., Lawlor, D.A., Davey
537 Smith, G., Sattar, N., Deanfield, J.E., 2010. Adiposity and cardiovascular risk factors in a large
538 contemporary population of pre-pubertal children. Eur. Heart J. 31, 3063–3072.
539 <https://doi.org/10.1093/eurheartj/ehq355>
- 540 Fervaha, G., Foussias, G., Agid, O., Remington, G., 2014. Motivational and neurocognitive deficits are
541 central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr.
542 Scand. 130, 290–299. <https://doi.org/10.1111/acps.12289>
- 543 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., Henderson, J.,
544 Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2013. Cohort Profile:
545 The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int. J.
546 Epidemiol. 42, 97–110. <https://doi.org/10.1093/ije/dys066>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 547 Fried, E.I., 2017. The 52 symptoms of major depression: Lack of content overlap among seven
548 common depression scales. *J. Affect. Disord.* 208, 191–197.
549 <https://doi.org/10.1016/j.jad.2016.10.019>
- 550 Gagne, C., Zika, O., Dayan, P., Bishop, S.J., 2020. Impaired adaptation of learning to contingency
551 volatility in internalizing psychopathology. *eLife* 9, e61387. <https://doi.org/10.7554/eLife.61387>
- 552 Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G.M., Nielsen, M.Ø.,
553 Glenthøj, L.B., Pezzella, P., Falkai, P., Dollfus, S., Gaebel, W., 2021. EPA guidance on
554 treatment of negative symptoms in schizophrenia. *Eur. Psychiatry* 64, e21.
555 <https://doi.org/10.1192/j.eurpsy.2021.13>
- 556 Gimeno, D., Kivimäki, M., Brunner, E.J., Elovainio, M., De Vogli, R., Steptoe, A., Kumari, M., Lowe,
557 G.D.O., Rumley, A., Marmot, M.G., Ferrie, J.E., 2009. Associations of C-reactive protein and
558 interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.
559 *Psychol. Med.* 39, 413–423. <https://doi.org/10.1017/S0033291708003723>
- 560 Golding, Pembrey, Jones, Team, T.A.S., 2001. ALSPAC—The Avon Longitudinal Study of Parents and
561 Children. *Paediatr. Perinat. Epidemiol.* 15, 74–87. <https://doi.org/10.1046/j.1365-3016.2001.00325.x>
- 562
563 Goldsmith, D.R., Rapaport, M.H., 2020. Inflammation and Negative Symptoms of Schizophrenia:
564 Implications for Reward Processing and Motivational Deficits. *Front. Psychiatry* 11, 46.
565 <https://doi.org/10.3389/fpsy.2020.00046>
- 566 Grice, J., 2001. Computing and evaluating factor scores. *Psychol. Methods* 6, 430–50.
- 567 Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O’Neal, L., McLeod, L., Delacqua, G.,
568 Delacqua, F., Kirby, J., Duda, S.N., REDCap Consortium, 2019. The REDCap consortium:
569 Building an international community of software platform partners. *J. Biomed. Inform.* 95,
570 103208. <https://doi.org/10.1016/j.jbi.2019.103208>
- 571 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009. Research electronic
572 data capture (REDCap)—a metadata-driven methodology and workflow process for providing
573 translational research informatics support. *J. Biomed. Inform.* 42, 377–381.
574 <https://doi.org/10.1016/j.jbi.2008.08.010>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 575 Hoang, U., Goldacre, M.J., Stewart, R., 2013. Avoidable mortality in people with schizophrenia or
576 bipolar disorder in England. *Acta Psychiatr. Scand.* 127, 195–201.
577 <https://doi.org/10.1111/acps.12045>
- 578 Hommel, J.D., Trinko, R., Sears, R.M., Georgescu, D., Liu, Z.W., Gao, X.B., Thurmon, J.J., Marinelli,
579 M., DiLeone, R.J., 2006. Leptin receptor signaling in midbrain dopamine neurons regulates
580 feeding. *Neuron* 51, 801–810.
- 581 Iasevoli, F., Avagliano, C., Altavilla, B., Barone, A., D'Ambrosio, L., Matrone, M., Notar Francesco, D.,
582 Razzino, E., de Bartolomeis, A., 2018. Disease Severity in Treatment Resistant Schizophrenia
583 Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive
584 Dysfunctions and Neurological Soft Signs. *Front. Psychiatry* 9, 553.
585 <https://doi.org/10.3389/fpsy.2018.00553>
- 586 Jerry, R.G., Lesley, V.C., 2006. Relationship Between Inflammation, Insulin Resistance and Type 2
587 Diabetes: Cause or Effect? *Curr. Diabetes Rev.* 2, 195–211.
- 588 Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., Lewis,
589 G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O'Donovan, M.C., Owen, M.J., Walters, J.T.,
590 Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia During
591 Adolescence in the General Population. *JAMA Psychiatry* 73, 221.
592 <https://doi.org/10.1001/jamapsychiatry.2015.3058>
- 593 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M.,
594 Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation,
595 and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian
596 Randomization Study. *JAMA Psychiatry* 78, 161–170.
597 <https://doi.org/10.1001/jamapsychiatry.2020.3436>
- 598 Khandaker, G.M., Dantzer, R., Jones, P.B., 2017. Immunopsychiatry: important facts. *Psychol. Med.*
599 47, 2229–2237. <https://doi.org/10.1017/S0033291717000745>
- 600 Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum
601 interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult
602 life: a population-based longitudinal study. *JAMA Psychiatry* 71, 1121–1128.
603 <https://doi.org/10.1001/jamapsychiatry.2014.1332>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 604 Konings, M., Bak, M., Hanssen, M., van Os, J., Krabbendam, L., 2006. Validity and reliability of the
- 605 CAPE: a self-report instrument for the measurement of psychotic experiences in the general
- 606 population. *Acta Psychiatr. Scand.* 114, 55–61. [https://doi.org/10.1111/j.1600-](https://doi.org/10.1111/j.1600-0447.2005.00741.x)
- 607 [0447.2005.00741.x](https://doi.org/10.1111/j.1600-0447.2005.00741.x)
- 608 Kruschke, J.K., Liddell, T.M., 2018. Bayesian data analysis for newcomers. *Psychon. Bull. Rev.* 25,
- 609 155–177. <https://doi.org/10.3758/s13423-017-1272-1>
- 610 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020.
- 611 Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the
- 612 NESDA study. *Brain. Behav. Immun.* 88, 174–183. <https://doi.org/10.1016/j.bbi.2020.04.002>
- 613 Leininger, G.M., Jo, Y.-H., Leshan, R.L., Louis, G.W., Yang, H., Barrera, J.G., Wilson, H., Opland,
- 614 D.M., Faouzi, M.A., Gong, Y., 2009. Leptin Acts via Leptin Receptor-Expressing Lateral
- 615 Hypothalamic Neurons to Modulate the Mesolimbic Dopamine System and Suppress Feeding.
- 616 *Cell Metab.* 10, 89–98. <https://doi.org/10.1016/j.cmet.2009.06.011>
- 617 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a
- 618 standardized assessment for use by lay interviewers. *Psychol. Med.* 22, 465–486.
- 619 <https://doi.org/10.1017/s0033291700030415>
- 620 Lis, M., Stańczykiewicz, B., Pawlik-Sobecka, L., Samochowiec, A., Reginia, A., Misiak, B., 2020.
- 621 Assessment of Appetite-Regulating Hormones Provides Further Evidence of Altered
- 622 Adipoinular Axis in Early Psychosis. *Front. Psychiatry* 11, 480.
- 623 <https://doi.org/10.3389/fpsy.2020.00480>
- 624 Makowski, D., Ben-Shachar, M.S., Chen, S.H.A., Lüdtke, D., 2019a. Indices of Effect Existence and
- 625 Significance in the Bayesian Framework. *Front. Psychol.* 10.
- 626 <https://doi.org/10.3389/fpsyg.2019.02767>
- 627 Makowski, D., Ben-Shachar, M.S., Lüdtke, D., 2019b. bayestestR: Describing Effects and their
- 628 Uncertainty, Existence and Significance within the Bayesian Framework. *J. Open Source*
- 629 *Softw.* 4, 1541. <https://doi.org/10.21105/joss.01541>
- 630 McElreath, R., 2018. Statistical Rethinking: A Bayesian Course with Examples in R and Stan,
- 631 Statistical Rethinking: A Bayesian Course with Examples in R and Stan.
- 632 <https://doi.org/10.1201/9781315372495>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 633 Metcalf, S.A., Jones, P.B., Nordstrom, T., Timonen, M., Mäki, P., Miettunen, J., Jääskeläinen, E.,
634 Järvelin, M.-R., Stochl, J., Murray, G.K., Veijola, J., Khandaker, G.M., 2017. Serum C-reactive
635 protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study.
636 Brain. Behav. Immun. 59, 253–259. <https://doi.org/10.1016/j.bbi.2016.09.008>
- 637 Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess, S., Penninx,
638 B.W.J.H., Khandaker, G.M., 2021. Association of inflammation with depression and anxiety:
639 evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts.
640 Mol. Psychiatry. <https://doi.org/10.1038/s41380-021-01188-w>
- 641 Milaneschi, Y., Lamers, F., Berk, M., Penninx, B.W.J.H., 2020. Depression Heterogeneity and Its
642 Biological Underpinnings: Toward Immunometabolic Depression. Biol. Psychiatry, Molecular
643 Underpinnings of Depression and Its Treatment 88, 369–380.
644 <https://doi.org/10.1016/j.biopsych.2020.01.014>
- 645 Milaneschi, Y., Lamers, F., Peyrot, W.J., Baune, B.T., Breen, G., Dehghan, A., Forstner, A.J., Grabe,
646 H.J., Homuth, G., Kan, C., Lewis, C., Mullins, N., Nauck, M., Pistis, G., Preisig, M., Rivera, M.,
647 Rietschel, M., Streit, F., Strohmaier, J., Teumer, A., Van der Auwera, S., Wray, N.R.,
648 Boomsma, D.I., Penninx, B.W.J.H., for the CHARGE Inflammation Working Group and the
649 Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, 2017.
650 Genetic Association of Major Depression With Atypical Features and Obesity-Related
651 Immunometabolic Dysregulations. JAMA Psychiatry 74, 1214–1225.
652 <https://doi.org/10.1001/jamapsychiatry.2017.3016>
- 653 Milaneschi, Y., Simmons, W.K., van Rossum, E.F.C., Penninx, B.W., 2019. Depression and obesity:
654 evidence of shared biological mechanisms. Mol. Psychiatry 24, 18–33.
655 <https://doi.org/10.1038/s41380-018-0017-5>
- 656 Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells, N., 2019. The
657 Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample
658 of index children in 2019. Wellcome Open Res. 4, 51.
659 <https://doi.org/10.12688/wellcomeopenres.15132.1>
- 660 Ong, K.K., Petry, C.J., Emmett, P.M., Sandhu, M.S., Kiess, W., Hales, C.N., Ness, A.R., Dunger, D.B.,
661 ALSPAC study team, 2004. Insulin sensitivity and secretion in normal children related to size at

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

birth, postnatal growth, and plasma insulin-like growth factor-I levels. *Diabetologia* 47, 1064–1070. <https://doi.org/10.1007/s00125-004-1405-8>

Osimo, E.F., Baxter, L.J., Lewis, G., Jones, P.B., Khandaker, G.M., 2019. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol. Med.* 49, 1958–1970. <https://doi.org/10.1017/S0033291719001454>

Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T., van Tilburg, W., 2001. Depression and cardiac mortality: results from a community-based longitudinal study. *Arch. Gen. Psychiatry* 58, 221–227. <https://doi.org/10.1001/archpsyc.58.3.221>

Perry, B.I., Burgess, S., Jones, H.J., Zammit, S., Upthegrove, R., Mason, A.M., Day, F.R., Langenberg, C., Wareham, N.J., Jones, P.B., Khandaker, G.M., 2021a. The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study. *PLoS Med.* 18, e1003455. <https://doi.org/10.1371/journal.pmed.1003455>

Perry, B.I., McIntosh, G., Weich, S., Singh, S., Rees, K., 2016. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. *Lancet Psychiatry* 3, 1049–1058. [https://doi.org/10.1016/S2215-0366\(16\)30262-0](https://doi.org/10.1016/S2215-0366(16)30262-0)

Perry, B.I., Stochl, J., Upthegrove, R., Zammit, S., Wareham, N., Langenberg, C., Winpenny, E., Dunger, D., Jones, P.B., Khandaker, G.M., 2021b. Longitudinal Trends in Childhood Insulin Levels and Body Mass Index and Associations With Risks of Psychosis and Depression in Young Adults. *JAMA Psychiatry*. <https://doi.org/10.1001/jamapsychiatry.2020.4180>

Perry, B.I., Upthegrove, R., Thompson, A., Marwaha, S., Zammit, S., Singh, S.P., Khandaker, G., 2019. Dysglycaemia, Inflammation and Psychosis: Findings From the UK ALSPAC Birth Cohort. *Schizophr. Bull.* 45, 330–338. <https://doi.org/10.1093/schbul/sby040>

Pillinger, T., Beck, K., Gobjila, C., Donocik, J.G., Jauhar, S., Howes, O.D., 2017. Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 74, 261–269. <https://doi.org/10.1001/jamapsychiatry.2016.3803>

Pulito-Cueto, V., Remuzgo-Martínez, S., Genre, F., Calvo-Alén, J., Aurrecochea, E., Llorente, I., Triguero-Martínez, A., Blanco, R., Llorca, J., Ruiz-Lucea, E., Rivera-García, N., Gualillo, O.,

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

López-Mejías, R., Castañeda, S., González-Gay, M.A., 2020. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin. Exp. Rheumatol.

R Development Core Team, 2017. R: A Language and environment for statistical computing. Vienna Austria R Found. Stat. Comput.

Stefanis, N.C., Hanssen, M., Smirnis, N.K., Avramopoulos, D.A., Evdokimidis, I.K., Stefanis, C.N., Verdoux, H., Van Os, J., 2002. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 32, 347–358.
<https://doi.org/10.1017/s0033291701005141>

Strauss, G.P., Whearty, K.M., Morra, L.F., Sullivan, S.K., Ossenfort, K.L., Frost, K.H., 2016. Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a Progressive Ratio task. Schizophr. Res. 170, 198–204.
<https://doi.org/10.1016/j.schres.2015.12.006>

Stubbs, B., Wang, A.K., Vancampfort, D., Miller, B.J., 2016. Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology 63, 144–154. <https://doi.org/10.1016/j.psyneuen.2015.09.026>

Sullivan, S.A., Kounali, D., Cannon, M., David, A.S., Fletcher, P.C., Holmans, P., Jones, H., Jones, P.B., Linden, D.E.J., Lewis, G., Owen, M.J., O'Donovan, M., Rammos, A., Thompson, A., Wolke, D., Heron, J., Zammit, S., 2020. A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder. Am. J. Psychiatry 177, 308–317.
<https://doi.org/10.1176/appi.ajp.2019.19060654>

Sun, F., Lei, Y., You, J., Li, C., Sun, L., Garza, J., Zhang, D., Guo, M., Scherer, P.E., Lodge, D., Lu, X.-Y., 2019. Adiponectin modulates ventral tegmental area dopamine neuron activity and anxiety-related behavior through AdipoR1. Mol. Psychiatry 24, 126–144.
<https://doi.org/10.1038/s41380-018-0102-9>

Timpson, N.J., Nordestgaard, B.G., Harbord, R.M., Zacho, J., Frayling, T.M., Tybjaerg-Hansen, A., Davey Smith, G., 2011. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int. J. Obes. 35, 300–308.
<https://doi.org/10.1038/ijo.2010.137>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 719 van Dielen, F.M.H., van't Veer, C., Schols, A.M., Soeters, P.B., Buurman, W.A., Greve, J.W.M., 2001.
720 Increased leptin concentrations correlate with increased concentrations of inflammatory
721 markers in morbidly obese individuals. *Int. J. Obes.* 25, 1759–1766.
722 <https://doi.org/10.1038/sj.ijo.0801825>
- 723 van Melle, J.P., de Jonge, P., Spijkerman, T.A., Tijssen, J.G.P., Ormel, J., van Veldhuisen, D.J., van
724 den Brink, R.H.S., van den Berg, M.P., 2004. Prognostic association of depression following
725 myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom.*
726 *Med.* 66, 814–822. <https://doi.org/10.1097/01.psy.0000146294.82810.9c>
- 727 Vancampfort, D., Stubbs, B., Mitchell, A.J., Hert, M.D., Wampers, M., Ward, P.B., Rosenbaum, S.,
728 Correll, C.U., 2015. Risk of metabolic syndrome and its components in people with
729 schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:
730 a systematic review and meta-analysis. *World Psychiatry* 14, 339–347.
731 <https://doi.org/10.1002/wps.20252>
- 732 Vanes, L.D., Mouchlianitis, E., Collier, T., Averbek, B.B., Shergill, S.S., 2018. Differential neural
733 reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. *Psychol.*
734 *Med.* 48, 2418–2427. <https://doi.org/10.1017/S0033291718000041>
- 735 Wagenmakers, E.-J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Love, J., Selker, R., Gronau, Q.F.,
736 Šmíra, M., Epskamp, S., Matzke, D., Rouder, J.N., Morey, R.D., 2018. Bayesian inference for
737 psychology. Part I: Theoretical advantages and practical ramifications. *Psychon. Bull. Rev.* 25,
738 35–57. <https://doi.org/10.3758/s13423-017-1343-3>
- 739 Wang, J., Huang, J., Yang, X.-H., Lui, S.S.Y., Cheung, E.F.C., Chan, R.C.K., 2015. Anhedonia in
740 schizophrenia: Deficits in both motivation and hedonic capacity. *Schizophr. Res.* 168, 465–474.
741 <https://doi.org/10.1016/j.schres.2015.06.019>
- 742 Wolf, D.H., Satterthwaite, T.D., Kantrowitz, J.J., Katchmar, N., Vandekar, L., Elliott, M.A., Ruparel, K.,
743 2014. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and
744 imaging measures. *Schizophr. Bull.* 40, 1328–1337. <https://doi.org/10.1093/schbul/sbu026>
- 745 Yudkin, J.S., Stehouwer, C.D.A., Emeis, J.J., Coppack, S.W., 1999. C-Reactive Protein in Healthy
746 Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction.
747 *Arterioscler. Thromb. Vasc. Biol.* 19, 972–978. <https://doi.org/10.1161/01.ATV.19.4.972>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

Zalli, A., Jovanova, O., Hoogendijk, W.J.G., Tiemeier, H., Carvalho, L.A., 2016. Low-grade

inflammation predicts persistence of depressive symptoms. *Psychopharmacology (Berl.)* 233,

1669–1678. <https://doi.org/10.1007/s00213-015-3919-9>

Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis, S.,

Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic experiences and psychotic disorders at age

18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort

study. *Am. J. Psychiatry* 170, 742–750. <https://doi.org/10.1176/appi.ajp.2013.12060768>